2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Review slidesets and expert analyses of key data from the 2021 Clinical Oncology Virtual Scientific Meeting!

Skin Cancer

Capsule Summary Slidesets

In KEYNOTE-054 Part 2, PFS and ORR after recurrence and crossover to pembrolizumab were similar to previous studies of immune checkpoint therapy for advanced melanoma, but pembrolizumab rechallenge had minimal activity.

Released: June 10, 2021

Neoadjuvant relatlimab plus nivolumab produced high rates of pCR and MPR in patients with resectable stage III melanoma with a tolerable safety profile.

Released: June 7, 2021

Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.

Released: June 7, 2021

Updated data from the LEAP 004 trial of lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progression on anti–PD-1/PD-L1 therapy resulted in durable responses and no new safety signals.

Released: June 9, 2021

Updated data continue to show encouraging safety and efficacy of TIL therapy with lifileucel in advanced/metastatic melanoma after progression on prior anti–PD-1/PD-L1 and BRAF ± MEK inhibitors.

Released: June 8, 2021

CheckMate 067 6.5-year follow-up finds a median overall survival of 72.1 months with nivolumab + ipilimumab in patients with advanced melanoma, durable benefits across subgroups, and no new safety signals.

Released: June 8, 2021

In the 5-year follow-up of the COLUMBUS trial, encorafenib plus binimetinib continues to show a survival benefit in patients with BRAF V600–mutant melanoma with no new safety signals.

Released: June 10, 2021

An update of the ABC study at 5 years shows that nivolumab plus ipilimumab has enduring activity in patients with asymptomatic melanoma brain metastases.

Released: June 10, 2021

Three-year follow-up of CheckMate 511 shows continued improved safety and comparable efficacy of NIVO3 + IPI1 vs NIVO1 + IPI3 for patients with advanced melanoma.

Released: June 6, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings